Market Overview

Wall Street's M&A Chatter From October 12: Kroger, Genesis Capital, Inotek Pharma-Rocket Pharma

Share:

The following are the M&A deals, rumors and chatter circulating on Wall Street for Thursday, October 12, 2017.

Inotek Pharmaceuticals Files Preliminary Proxy Statement for Proposed Merger with Rocket Pharmaceuticals

The Proxy Statement:

Inotek Pharmaceuticals Corp (NASDAQ: ITEK) announced in a filing with the SEC of the company's preliminary proxy statement in connection with the previously announced proposed merger with Rocket Pharmaceuticals. Rocket shareholders will receive shares of newly issued Inotek common shares in a private placement at the closing, with Rocket shareholders owning approximately 81 percent of the combined company.

The merger is subject to approval by Inotek stockholders and is expected to close in Q1 of 2018.

Inotek Pharmaceuticals closed Thursday at $2.95, and traded as high as $3.77 after-hours.

Kroger Said to Receive Interest from 7-Eleven Owner

The Rumor:

Shares of Kroger Co (NYSE: KR) traded higher as DealReporter said the company is attracting takeover interest for its convenience stores, including from 7-11 owner Seven & I Holdings and Alimentation Couche-Tard Inc (USA) (OTC: ANCTF). Kroger announced it was intent on exploring strategic alternatives for the convenience store business.

Kroger closed at $21.00, up 22 cents.

Genesis Capital

The Deal:

Specialty commercial lending platform, Genesis Capital, LLC, announced it's being acquired from funds managed by Oaktree Capital Management L.P. and management. Terms of the transaction were not disclosed.

Posted-In: M&A News Rumors

 

Related Articles (ANCTF + ITEK)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

28 Stocks Moving In Friday's Pre-Market Session

Lightning Round: Jim Cramer Weighs In On Bristol-Myers Squibb, Mazor Robotics And More